Join us throughout November and December at upcoming investor conferences.
Learn more: bit.ly/48NlDw8
Breaking News:
At the 2026 @American_Heart (AHA) Scientific Sessions, we presented detailed clinical data for ARO-DIMER-PA, the first investigational dual-functional sIRNA treatment for mixed hyperlipidemia.
Learn More: arrowheadpharma.com/en-us/ne…
(1/2)
#FCSAwarenessDay highlights the importance of advancing understanding of Familial Chylomicronemia Syndrome (FCS), a rare genetic disorder that can result in recurrent acute pancreatitis. Progress takes all of us: patients, advocates & experts.
#HighTriglycerides
Our new SHASTA-3 and SHASTA-4 data was published by @NEJM, showing percentage change in fasting serum triglyceride levels from baseline and acute pancreatitis risk reduction in adults with severe hypertriglyceridemia (sHTG).
Today, we've announced a refinancing of our existing credit facility with Sixth Street.
Learn more in today’s announcement:bit.ly/4sErEEC
Join Arrowhead leadership to discuss 2026 fiscal year-end results during a webcast and conference call.
To learn more or register for the event, visit: bit.ly/47Wh8PG
Breaking News: Arrowhead Pharmaceuticals to present important clinical data at the American Heart Association Scientific Sessions 2026.
Learn more: arrowheadpharma.com/en-us/ne…
Today we announced interim Phase 1/2a clinical data for ARO-MAPT.
The results represent an important step in clinical validation of our TRiM platform for delivering siRNA to the central nervous system.
Join today’s webinar to learn more: bit.ly/3VMXyCD
The FDA has granted plozasiran entry into the Split Real Time Application Review (STAR) pilot program for severe hypertriglyceridemia (sHTG), qualifying the supplemental application for 6-month priority review vs the 10-month standard review.
Learn more: bit.ly/4dtDqLU
We’re in Orlando through October 4 for #NLAFall. Our teams are excited to share the latest in our cardiometabolic advances at Booth 202.
Join Arrowhead leadership and experts on Oct. 14th for an R&D webinar discussing our CNS pipeline and interim clinical data from the Phase 1/2 study of ARO-MAPT.
Learn more and register for the event: bit.ly/3VeYijK
We're pleased to announce positive interim data from the Phase 1/2a study of our investigational dual-functional RNAi therapeutic, ARO-DIMER-PA, supporting our novel approach for the treatment of cardiometabolic disease.
Learn more here: bit.ly/4AfEtIZ
Arrowhead Pharmaceuticals will be participating in several investor conferences this month. Members of our leadership team will share updates on our RNAi pipeline and key clinical programs.
Details on presentation times and webcast links can be found here: bit.ly/4xAWz6n
Breaking News: At the European Society of Cardiology Congress (ESC), we presented Phase 3 SHASTA-3 & SHASTA-4 data demonstrating our investigational siRNA therapy reduced acute pancreatitis events in patients with severe hypertriglyceridemia.
Learn more: arrowheadpharma.com/en-us/ne…
News Update:
Today we announced that we will present important new data at the upcoming European Society of Cardiology (ESC) on August 30 and 31 in Munich, Germany.
Learn more: arrowheadpharma.com/en-us/ne…
36
1,005
People living with FCS in Germany now have access to REDEMPLO® (plozasiran) as a new treatment option. REDEMPLO® is listed in the Lauer-Taxe® database as an adjunct to diet to reduce triglyceride levels in adult patients with FCS.
Learn more here: bit.ly/3U4kTim
We are hosting a conference call and webcast today at 4:30 p.m. ET to discuss fiscal 2026 third quarter financial results and provide a corporate update.
To learn more or participate in the conference call: bit.ly/4gbSU8P
#WeAreArrowhead
We’ve acquired an FDA Rare Pediatric Disease Priority Review Voucher (PRV) to be used for an upcoming sNDA submission for patients with severe hypertriglyceridemia (sHTG)
Read the full announcement: bit.ly/3TC7VrU






